Interferon-γ-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression

OncoImmunology

Volumn 4, Issue 6, 2015, Pages

  Bellucci, Roberto ^a,b,c   Martin, Allison ^a   Bommarito, Davide ^a   Wang, Kathy ^a   Hansen, Steen H ^b,c,d   Freeman, Gordon J ^a,b,c   Ritz, Jerome ^a,b,c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

IFN ; JAK1 JAK2; NK cells; PD 1 PD L1

Indexed keywords

GAMMA INTERFERON; JANUS KINASE; JANUS KINASE 1; JANUS KINASE 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROGRAMMED DEATH 1 LIGAND 1; STAT PROTEIN; SYNDECAN 1;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ARTICLE; BONE MARROW BIOPSY; CANCER IMMUNOTHERAPY; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; ENZYME INHIBITION; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; MULTIPLE MYELOMA; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECEPTOR UPREGULATION; TUMOR CELL DESTRUCTION; WESTERN BLOTTING;

EID: 84940826256     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1008824     Document Type: Article

References (51)

1. Caligiuri MA. Human natural killer cells. Blood 2008; 112:461-9; PMID:18650461; http://dx.doi.org/ 10.1182/blood-2007-09-077438
2. Orr MT, Lanier LL. Natural killer cell education and tolerance. Cell 2010; 142:847-56; PMID:20850008; http://dx.doi.org/10.1016/j.cell.2010.08.031
3. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, Yokoyama WM, Ugolini S. Innate or adaptive immunity? The example of natural killer cells. Science 2011; 331:44-9; PMID:21212348; http://dx. doi.org/10.1126/science.1198687
4. Lanier LL. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol 2008; 9:495-502; PMID:18425106; http://dx.doi.org/10.1038/ni1581
5. Robertson MJ, Ritz J. Biology and clinical relevance of human natural killer cells. Blood 1990; 76:2421-38; PMID:2265240
6. Smyth MJ, Dunn GP, Schreiber RD. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. AdvImmunol 2006; 90:1-50; PMID:16730260; http://dx.doi.org/10.1016/S0065-2776(06)90001-7
7. Bellucci R, Nguyen HN, Martin A, Heinrichs S, Schinzel AC, Hahn WC, Ritz J. Tyrosine kinase pathways modulate tumor susceptibility to natural killer cells. J Clin Invest 2012; 122:2369-83; PMID:22684105; http://dx.doi.org/10.1172/JCI58457
8. Chen E, Staudt LM, Green AR. Janus kinase deregulation in leukemia and lymphoma. Immunity 2012; 36:529-41; PMID:22520846; http://dx.doi.org/ 10.1016/j.immuni.2012.03.017
9. Jelinek J, Oki Y, Gharibyan V, Bueso-Ramos C, Prchal JT, Verstovsek S, Beran M, Estey E, Kantarjian HM, Issa JP. JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood 2005; 106:3370-3; PMID:16037387; http://dx. doi.org/10.1182/blood-2005-05-1800
10. Lacronique V, Boureux A, Valle VD, Poirel H, Quang CT, Mauchauffe M, Berthou C, Lessard M, Berger R, Ghysdael J et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 1997; 278:1309-12; PMID:9360930; http://dx.doi. org/10.1126/science.278.5341.1309
11. Darnell JE, Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994; 264:1415-21; PMID:8197455; http://dx.doi.org/ 10.1126/science.8197455
12. Matsuzawa T, Kim BH, Shenoy AR, Kamitani S, Miyake M, Macmicking JD. IFN-gamma Elicits Macrophage Autophagy via the p38 MAPK Signaling Pathway. J Immunol 2012; 189:813-8; PMID:22675202; http://dx.doi.org/10.4049/jimmunol.1102041
13. Navarro A, Anand-Apte B, Tanabe Y, Feldman G, Larner AC. A PI-3 kinase-dependent, Stat1-independent signaling pathway regulates interferon-stimulated monocyte adhesion. J LeukocBiol 2003; 73:540-5; PMID:12660229; http://dx.doi.org/10.1189/ jlb.1002508
14. O'Shea JJ, Holland SM, Staudt LM. JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med 2013; 368:161-70; PMID:23301733; http://dx. doi.org/10.1056/NEJMra1202117
15. Farag SS, Caligiuri MA. Human natural killer cell development and biology. Blood Rev 2006; 20:123-37; PMID:16364519; http://dx.doi.org/10.1016/j. blre.2005.10.001
16. Vivier E, Tomasello E, Baratin M,Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol 2008; 9:503-10; PMID:18425107; http://dx.doi.org/ 10.1038/ni1582
17. Alter G, Malenfant JM, Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. JImmunolMethods 2004; 294:15-22; PMID:15604012; http://dx.doi.org/10.1016/j. jim.2004.08.008
18. Depraetere H, Depla E, Haelewyn J, De Ley M. An anti-idiotypic antibody with an internal image of human interferon-gamma and human interferongamma-like antiviral activity. EurJBiochem 2000; 267:2260-7; PMID:10759849; http://dx.doi.org/ 10.1046/j.1432-1327.2000.01231.x
19. Lanier LL. NK cell recognition. Annu Rev Immunol 2005; 23:225-74; PMID:15771571; http://dx.doi.org/ 10.1146/annurev.immunol.23.021704.115526
20. Maio M, Altomonte M, Tatake R, Zeff RA, Ferrone S. Reduction in susceptibility to natural killer cell-mediated lysis of human FO-1 melanoma cells after induction of HLA class I antigen expression by transfection with B2m gene. J Clin Invest 1991; 88:282-9; PMID:1905328; http://dx.doi.org/10.1172/ JCI115289
21. Beatty GL, Paterson Y. IFN-gamma can promote tumor evasion of the immune system in vivo by downregulating cellular levels of an endogenous tumor antigen. J Immunol 2000; 165:5502-8; PMID:11067903; http://dx.doi.org/10.4049/jimmunol.165.10.5502
22. Boraschi D, Censini S, Tagliabue A. Interferon-gamma reduces macrophage-suppressive activity by inhibiting prostaglandin E2 release and inducing interleukin 1 production. J Immunol 1984; 133:764-8; PMID:6330202
23. Naganuma H, Sasaki A, Satoh E, Nagasaka M, Nakano S, Isoe S, Nukui H. Down-regulation of transforming growth factor-beta and interleukin-10 secretion from malignant glioma cells by cytokines and anticancer drugs. JNeurooncol 1998; 39:227-36; PMID:9821108; http://dx.doi.org/10.1023/ A:1005902120612
24. Dolen Y, Esendagli G. Myeloid leukemia cells with a B7-2(+) subpopulation provoke Th-cell responses and become immuno-suppressive through the modulation of B7 ligands. Eur J Immunol 2013; 43:747-57; PMID:23175469; http://dx.doi.org/10.1002/ eji.201242814
25. Velu V, Titanji K, Zhu B, Husain S, Pladevega A, Lai L, Vanderford TH, Chennareddi L, Silvestri G, Freeman GJ et al. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature 2009; 458:206-10; PMID:19078956; http://dx.doi.org/10.1038/ nature07662
26. Yao S, Zhu Y, Chen L. Advances in targeting cell surface signalling molecules for immune modulation. NatRev Drug Discov 2013; 12:130-46; PMID:23370250; http://dx.doi.org/10.1038/nrd3877
27. Zitvogel L, Kroemer G. Targeting PD-1/PD-L1 interactions for cancer immunotherapy. Oncoimmunology 2012; 1:1223-5; PMID:23243584; http://dx.doi.org/ 10.4161/onci.21335
28. Benson DM, Jr, Bakan CE, Mishra A, Hofmeister CC, Efebera Y, Becknell B, Baiocchi RA, Zhang J, Yu J, Smith MK et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 2010; 116:2286-94; PMID:20460501; http://dx.doi.org/10.1182/blood-2010-02-271874
29. Wiesmayr S, Webber SA, Macedo C, Popescu I, Smith L, Luce J, Metes D. Decreased NKp46 and NKG2D and elevated PD-1 are associated with altered NK-cell function in pediatric transplant patients with PTLD. Eur J Immunol 2012; 42:541-50; PMID:22105417; http://dx.doi.org/10.1002/eji.201141832
30. Coughlin CM, Salhany KE, Gee MS, LaTemple DC, Kotenko S, Ma X, Gri G, Wysocka M, Kim JE, Liu L et al. Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity 1998; 9:25-34; PMID:9697833; http://dx.doi.org/10.1016/S1074-7613(00)80585-3
31. Dighe AS, Richards E, Old LJ, Schreiber RD. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity 1994; 1:447-56; PMID:7895156; http://dx.doi.org/10.1016/1074-7613(94)90087-6
32. Dunn GP, Sheehan KC, Old LJ, Schreiber RD. IFN unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression. Cancer Res 2005; 65:3447-53; PMID:15833880
33. Fisher PB, Miranda AF, Babiss LE. Measurement of the effect of interferons on cellular differentiation in murine and human melanoma cells. Methods Enzymol 1986; 119:611-8; PMID:3762411; http://dx.doi.org/ 10.1016/0076-6879(86)19082-3
34. Kortylewski M, Komyod W, Kauffmann ME, Bosserhoff A, Heinrich PC, Behrmann I. Interferon-gammamediated growth regulation of melanoma cells: involvement of STAT1-dependent and STAT1-independent signals. JInvestDermatol 2004; 122:414-22; PMID:15009724; http://dx.doi.org/10.1046/j.0022-202X.2004.22237.x
35. Creagan ET, Ahmann DL, Long HJ, Frytak S, Sherwin SA, Chang MN. Phase II study of recombinant interferon-gamma in patients with disseminated malignant melanoma. Cancer TreatReports 1987; 71:843-4; PMID:3113730
36. Meyskens FL, Jr, Kopecky K, Samson M, Hersh E, Macdonald J, Jaffe H, Crowley J, Coltman C. Recombinant human interferon gamma: adverse effects in high-risk stage I and II cutaneous malignant melanoma. J Natl Cancer Inst 1990; 82:1071; PMID:2112201; http://dx.doi.org/10.1093/jnci/82.12.1071-a
37. Lollini PL, Bosco MC, Cavallo F, De Giovanni C, Giovarelli M, Landuzzi L, Musiani P, Modesti A, Nicoletti G, Palmieri G et al. Inhibition of tumor growth and enhancement of metastasis after transfection of the gamma-interferon gene. Int J Cancer 1993; 55:320-9; PMID:8370628; http://dx.doi.org/10.1002/ ijc.2910550224
38. Taniguchi K, Petersson M, Hoglund P, Kiessling R, Klein G, Karre K. Interferon gamma induces lung colonization by intravenously inoculated B16 melanoma cells in parallel with enhanced expression of class I major histocompatibility complex antigens. ProcNatlAcadSci US A 1987; 84:3405-9; PMID:3106968; http://dx.doi.org/10.1073/ pnas.84.10.3405
39. Bukowski JF, Welsh RM. Inability of interferon to protect virus-infected cells against lysis by natural killer (NK) cells correlates with NK cell-mediated antiviral effects in vivo. J Immunol 1985; 135:3537-41; PMID:2413125
40. Zaidi MR, Merlino G. The two faces of interferongamma in cancer. Clin Cancer Res 2011; 17:6118-24; PMID:21705455; http://dx.doi.org/10.1158/1078-0432.CCR-11-0482
41. Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 1999; 5:1365-9; PMID:10581077; http://dx.doi.org/ 10.1038/70932
42. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000; 192:1027-34; PMID:11015443; http://dx. doi.org/10.1084/jem.192.7.1027
43. Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ, Schreiber RD. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. ProcNatlAcadSci U S A 1998; 95:7556-61; PMID:9636188; http://dx.doi. org/10.1073/pnas.95.13.7556
44. Pena J, Alonso C, Solana R, Serrano R, Carracedo J, Ramirez R. Natural killer susceptibility is independent of HLA class I antigen expression on cell lines obtained from human solid tumors. Eur J Immunol 1990; 20:2445-8; PMID:1701392; http://dx.doi.org/ 10.1002/eji.1830201113
45. Brown JA, Dorfman DM, Ma FR, Sullivan EL, Munoz O, Wood CR, Greenfield EA, Freeman GJ. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol 2003; 170:1257-66; PMID:12538684; http://dx.doi.org/10.4049/jimmunol.170.3.1257
46. Chen J, Feng Y, Lu L, Wang H, Dai L, Li Y, Zhang P. Interferon-gamma-induced PD-L1 surface expression on human oral squamous carcinoma via PKD2 signal pathway. Immunobiology 2012; 217:385-93; PMID:22204817; http://dx.doi.org/10.1016/j. imbio.2011.10.016
47. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366:2455-65; PMID:22658128; http://dx.doi. org/10.1056/NEJMoa1200694
48. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443-54; PMID:22658127; http://dx.doi.org/10.1056/NEJMoa1200690
49. Gong JH, Maki G, Klingemann HG. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 1994; 8:652-8; PMID:8152260
50. Robertson MJ, Cochran KJ, Cameron C, Le JM, Tantravahi R, Ritz J. Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia. ExpHematol 1996; 24:406-15; PMID:8599969
51. Fuller MJ, Callendret B, Zhu B, Freeman GJ, Hasselschwert DL, Satterfield W, Sharpe AH, Dustin LB, Rice CM, Grakoui A et al. Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1). ProcNatlAcadSci U S A 2013; 110:15001-6; PMID:23980172; http://dx.doi. org/10.1073/pnas.1312772110